MedTrace Logo

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

NCT00960245 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.

Conditions

Interventions

DRUG

Nadolol (1 x 80 mg) Tablets (Invamed, Inc)

DRUG

Corgard (1 x 80 mg) Tablets (Bristol Laboratories)

Sponsors & Collaborators

Principal Investigators

  • Terry L. Wolff, D.O. · MeritCare Broadway Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1994-07-31
Primary Completion
1994-07-31
Completion
1994-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960245 on ClinicalTrials.gov